Inhibrx Inc (INBX)
34.10
0.00 (0.00%)
USD |
NASDAQ |
Apr 23, 16:00
Inhibrx Total Long Term Debt (Quarterly): 206.97M for Dec. 31, 2023
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 206.97M |
September 30, 2023 | 205.72M |
June 30, 2023 | 204.48M |
March 31, 2023 | 203.26M |
December 31, 2022 | 202.07M |
September 30, 2022 | 170.82M |
June 30, 2022 | 169.80M |
March 31, 2022 | 109.14M |
December 31, 2021 | 70.47M |
September 30, 2021 | 70.07M |
June 30, 2021 | 69.67M |
Date | Value |
---|---|
March 31, 2021 | 29.44M |
December 31, 2020 | 29.24M |
September 30, 2020 | 9.821M |
June 30, 2020 | 1.875M |
March 31, 2020 | 0.00 |
December 31, 2019 | 33.93M |
September 30, 2019 | 0.00 |
June 30, 2019 | 32.11M |
March 31, 2019 | 8.085M |
June 30, 2018 | 0.00 |
March 31, 2018 | 0.00 |
Total Long Term Debt Definition
Total Long Term Debt is the current and non-current portion of debt that a company holds. Current Portion debt are obligations of a company lasting shorter than a year. This is found in a company's current liabilities on its balance sheet.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
Sep 2019
206.97M
Maximum
Dec 2023
95.73M
Average
70.07M
Median
Sep 2021
Total Long Term Debt (Quarterly) Benchmarks
Johnson & Johnson | 0.00 |
Gilead Sciences Inc | 24.99B |
Outlook Therapeutics Inc | -- |
Axonics Inc | 0.00 |
NovaBay Pharmaceuticals Inc | 1.137M |